series-a
Stage
2018
Founded
1
Investors
About
Kivu Bioscience is a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, utilizing proprietary GlycoConnect technology to improve stability and reduce off-target toxicity.
Explore Kivu Bioscience's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.